4.08

5.15% 0.20

Kalaris Therapeutics Inc (KLRS)

Overview News Price History Discussions Forecast

Kalaris Therapeutics Inc stock is traded at $4.08, with a volume of 28,090. It is up +5.15% in the last 24 hours and down -10.33% over the past month. Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Previous Close:

$3.88

Open:

$4.02

24h Volume:

28,090

Relative Volume:

0.11

Market Cap:

$97.12M

Revenue:

Net Income/Loss:

$-44.10M

P/E Ratio:

-1.9091

EPS:

-2.1371

Net Cash Flow:

$-49.09M

1W Performance:

+0.25%

1M Performance:

-10.33%

6M Performance:

-52.83%

1Y Performance:

+79.74%

1-Day Range:

$3.88

$4.15

1-Week Range:

$3.84

$4.18

52-Week Range:

$2.31

$11.88

Kalaris Therapeutics Inc Stock (KLRS) Company Profile

Name

Kalaris Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

650-249-2727

Address

400 CONNELL DRIVE, BERKELEY HEIGHTS

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

KLRS's Discussions on Twitter

Compare KLRS vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KLRS Kalaris Therapeutics Inc	4.08	93.79M	0	-44.10M	-49.09M	-2.1371
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-16-26	Initiated	Morgan Stanley	Overweight
Dec-23-25	Initiated	Chardan Capital Markets	Buy
Nov-03-25	Initiated	Citizens JMP	Mkt Outperform
Sep-03-25	Initiated	Raymond James	Strong Buy
Jul-23-25	Resumed	Piper Sandler	Neutral
May-07-25	Initiated	Leerink Partners	Outperform
Apr-08-25	Initiated	William Blair	Outperform

View All

Kalaris Therapeutics Inc Stock (KLRS) Latest News

Kalaris Therapeutics Inc (KLRS)

Kalaris Therapeutics Inc Stock (KLRS) Company Profile

Compare KLRS vs VRTX, REGN, ARGX, RVMD, ONC

Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades

Kalaris Therapeutics Inc Stock (KLRS) Latest News

Kalaris Therapeutics Reports Q2 Financial Results, Advances Clinical Program - VisionMonday.com

Kalaris Therapeutics, Inc. 2Q 2026: Net loss $(11.5M), Diluted EPS $(0.48) — 10-Q Summary - TradingView

Kalaris Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Kalaris Therapeutics Q2 Results: EPS beats estimate, losses narrow 21% YoY - scanx.trade

Kalaris Therapeutics, Inc. (NASDAQ: KLRS) Share Price, KLRS Stock News, KLRS Share Price & Updates - kalkine.ca

Form 8K Kalaris Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia

Kalaris Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Kalaris Therapeutics (NASDAQ:KLRS) Announces Earnings Results - MarketBeat

Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times

Kalaris Therapeutics Reports Q2 2026 Results and Advances Phase 1b/2 TH103 Study for Neovascular AMD - Quiver Quantitative

Kalaris Reports Q2 2026: $11.5M Quarterly Net Loss; $93.5M Cash on Hand - TradingView

KLRS: TH103 clinical progress and strong cash position support operations into Q4 2027 - TradingView

Kalaris Reports $11.5 Million Q2 Net Loss and TH103 Updates - Quiver Quantitative

BRIEF-Kalaris Therapeutics Inc Q2 Operating Income USD -12.386 Million Vs. IBES Estimate USD -12.5 Million - TradingView

KLRS Stock Price and Chart — NASDAQ:KLRS - TradingView

Kalaris Therapeutics Inc. (KLRS) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com

Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4%Here's What Happened - MarketBeat

KLRS: Abbott Cooper PLLC Announces Investigation on Behalf - GlobeNewswire

Investigation launched into Kalaris Therapeutics board for possible fiduciary breaches since 2024 - pluang.com

Kalaris Therapeutics (KLRS) Holds Gains Near $3.51 as Stock Consolidates Between Key LevelsValue Stock Ideas - dars.gov.et

Kalaris Therapeutics (KLRS) Sees Modest Gain as Stock Holds Above SupportMA Cross Alert - dars.gov.et

Kalaris Therapeutics Inc (KLRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Kalaris Therapeutics Inc (KLRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Kalaris Therapeutics Inc (KLRS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Kalaris Therapeutics Inc (KLRS) Cash Flow - TradingKey

Kalaris Therapeutics Inc (KLRS) Valuation: PE, PB & Fair Value Analysis - TradingKey

TradingKey - TradingKey

KLRS|Kalaris Therapeutics Inc|Price:3.730|Chg%:-0.190 - TradingKey

KLRS|Kalaris Therapeutics Inc|Price:3.830|Chg%:-0.110 - tradingkey.com

Kalaris Therapeutics Inc (KLRS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Kalaris Therapeutics (KLRS) Drops 3.7% as Stock Tests Key Support ZoneEarnings Quality Factor - dars.gov.et

Kalaris appoints Liisa Bayko as CFO - MSN

Why is Kalaris Therapeutics stock gaining Friday? - MSN

Kalaris Therapeutics Appoints Liisa Bayko as New Chief Financial Officer - VisionMonday.com

Kalaris Therapeutics files Form 3 for CFO Liisa Ann Bayko - Bitget

Kalaris Therapeutics appoints Liisa Bayko as CFO By Investing.com - Investing.com Nigeria

Kalaris Therapeutics appoints Liisa Bayko as CFO - Investing.com

Kalaris Therapeutics stock falls despite naming new CFO By Investing.com - Investing.com South Africa

Kalaris Therapeutics Appoints Liisa Bayko as New CFO - Contract Pharma

Kalaris Therapeutics stock falls despite naming new CFO - Investing.com

Kalaris Therapeutics, Inc. Announces Appointment of Liisa Bayko to Chief Financial Officer, Effective July 20, 2026 - marketscreener.com

Kalaris Therapeutics Strengthens Financial Leadership With New CFO - TipRanks

Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer - The Manila Times

After more than two decades in biotech finance, Liisa Bayko joins Kalaris - Stock Titan

Kalaris Therapeutics appoints Liisa Bayko as Chief Financial Officer - scanx.trade

Kalaris Therapeutics Slides Nearly 5% as Support Levels Come into FocusFear Greed Extreme - dars.gov.et

Enterprise value to revenue forward of Kalaris Therapeutics, Inc. – NASDAQ:KLRS - TradingView

KLRS Dips After Intraday Spike Draws Trader Interest - timothysykes.com

Kalaris Therapeutics Shares Rise After More Positive Data From TH103 Trial - Moomoo

KLRS Stock Dips As Traders React To Volatile Intraday Spike - StocksToTrade

Kalaris Therapeutics Inc Stock (KLRS) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to KLRS